We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
US Patent Granted for Verona Pharma’s RPL554
News

US Patent Granted for Verona Pharma’s RPL554

US Patent Granted for Verona Pharma’s RPL554
News

US Patent Granted for Verona Pharma’s RPL554

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "US Patent Granted for Verona Pharma’s RPL554"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Verona Pharma plc has announced that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554.

The patent is the fourth patent issued for RPL554 and related compounds in the US.

RPL554, Verona Pharma's lead drug candidate, is a dual phosphodiesterase 3 and 4 inhibitor with both bronchodilator and anti-inflammatory properties.

RPL554 is being developed for the treatment of patients with chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.

The Company is currently carrying out clinical trials of the drug to further characterize its bronchodilator and anti-inflammatory effects.

Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: “We are growing the intellectual property portfolio around the RPL554 programme and the issue of this new US Patent strengthens and harmonizes our international patent estate around RPL554 and provides exclusivity in one of the world’s leading pharmaceutical markets. We continue to develop our intellectual property rights as this is a key part of Verona Pharma’s strategy.”

Advertisement